X4 Pharmaceuticals (NASDAQ:XFOR) Trading Down 4.9% - Here's What Happened

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report)'s share price fell 4.9% during trading on Tuesday . The stock traded as low as $5.31 and last traded at $5.07. 19,287 shares were traded during mid-day trading, a decline of 79% from the average session volume of 91,837 shares. The stock had previously closed at $5.34.

Analysts Set New Price Targets

Several brokerages recently issued reports on XFOR. Cantor Fitzgerald reissued an "overweight" rating and set a $90.00 target price on shares of X4 Pharmaceuticals in a research note on Wednesday, March 26th. HC Wainwright increased their price objective on shares of X4 Pharmaceuticals from $1.50 to $7.00 and gave the company a "buy" rating in a report on Friday.

X4 Pharmaceuticals Stock Down 0.7 %

The company has a fifty day moving average price of $7.86 and a 200-day moving average price of $13.28. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. The firm has a market capitalization of $646.89 million, a PE ratio of -41.44 and a beta of 0.58.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.13) by $4.17. The business had revenue of $28.81 million for the quarter, compared to analysts' expectations of $7.03 million. As a group, analysts expect that X4 Pharmaceuticals, Inc. will post -0.68 earnings per share for the current year.

Institutional Trading of X4 Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Cantor Fitzgerald L. P. bought a new stake in shares of X4 Pharmaceuticals during the fourth quarter valued at approximately $30,000. Atria Wealth Solutions Inc. bought a new stake in X4 Pharmaceuticals during the 4th quarter valued at $44,000. Wells Fargo & Company MN lifted its holdings in shares of X4 Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 78,518 shares of the company's stock worth $58,000 after buying an additional 26,763 shares during the period. Bank of America Corp DE grew its position in shares of X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company's stock worth $98,000 after buying an additional 22,485 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of X4 Pharmaceuticals by 233.0% during the fourth quarter. SG Americas Securities LLC now owns 183,152 shares of the company's stock valued at $134,000 after buying an additional 128,148 shares during the period. 72.03% of the stock is currently owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.